Vor BiopharmaVOR
Recorded

Vor Biopharma Jefferies Global Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 0Duration26 minParticipants3

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Farzin HaqueBiotechnology Equity Research Analyst

Good to go? Hi, everyone. My name is Farzin Haque, one of the biotech analysts at Jefferies. It is my pleasure to introduce Jean-Paul Kress, CEO, and Jeremy Sokolove, CMO of Vor Biopharma. This is a fireside chat format. Thank you for joining us today. Maybe to start off, can you provide a quick overview of the company and those that are new to the story?

Jean-Paul KressCEO

Sure. Good morning. Thanks for having us. Pleasure to be here with Jeremy and the rest of the crew. Vor is building a leading BAFF/APRIL franchise. We believe BAFF/APRIL is the perfect modality to change the standard of care in many autoimmune diseases. Our lead asset is called telitacicept, and it is in three phase III in myasthenia gravis, generalized myasthenia gravis, in Sjögren's disease, and soon in ocular myasthenia gravis. We have best-in-disease data from China, and we aim at showing that globally, we will have also best-in-disease data in these first indications. I mentioned the fact that we are aiming at building a franchise.

Jean-Paul KressCEO

We announced last week that we in-licensed a second asset, a second BAFF/APRIL inhibitor, best-in-class, long-acting BAFF/APRIL inhibitor, which is called RC298, and we believe this will expand our aims at new indications beyond what we are exploring with telitacicept, and establish us as the leading company in BAFF/APRIL inhibitor. We have a healthy cash balance with around $480 million, which brings us to early 2029.

Farzin HaqueBiotechnology Equity Research Analyst

Great. On the MG, it just completed enrollment recently, so can you talk more about the patient baseline characteristics? Will you publish them or ahead of the top line? Essentially, I am trying to get at is that, are there any notable differences between the China phase III and the global phase III?

Jeremy SokoloveChief Medical Officer

Sure. The current global phase III in MG is slightly different than the China population, very similar to the global populations we have seen recently in MG studies. The disease duration is slightly longer than was seen in China. China had a uniquely short disease duration and slightly younger population enrolled. This is typical of Chinese academic medical centers and their ability to enroll that population. But the good news is it looks very much like the global MG phase III studies we have seen of recent from the likes of Amgen, UCB, J&J. We do anticipate a representative population very similar to what has been seen globally and not significantly differentiated from what was seen in China, other than the two things, the two characteristics I mentioned.

Farzin HaqueBiotechnology Equity Research Analyst

Do you have any FcRn prior exposure, like specifically those cohorts? Basically, can you say anything meaningful about whether telitacicept can rescue or deepen responses after the FcRns?

Jeremy SokoloveChief Medical Officer

Yeah. We have a small subset of patients who are prior FcRn inadequate responders enrolled in the UPSTREAM MG study. It is hopefully enough patients to numerically show the ability for telitacicept to acquire a response in patients previously failed FcRns. It is probably not enough to do a formally powered statistical subgroup analysis, but it is also a good opportunity for us to be the first drug that tested this in their global phase III.

Farzin HaqueBiotechnology Equity Research Analyst

Got it. The study is powered for actually greater than 2-point placebo-adjusted MG-ADL delta against the 4.8 in China. So you have a meaningful cushion, but what steps have you taken, such as the run-in period, centralized endpoint training, or background therapy stabilization protocols to minimize the placebo drift to- Yeah.

Jeremy SokoloveChief Medical Officer

The main thing is that we really wanted to make sure patients who were on background therapies were either taking their background therapies or had discontinued them long enough ago that they wouldn't be confounding the placebo effect. We did that really by having source verification whenever somebody was coming in on a background therapy to make sure they were adherent, so what we thought was a stable background regimen was in fact a stable background regimen. We also really do our best to make sure that patients remain adherent to their background therapies during the course of the randomized period. At the end of the randomized period, they can obviously change them at the discretion of the investigator.

Farzin HaqueBiotechnology Equity Research Analyst

Got it. Beyond the mean, the MG-ADL delta, what responder profile would make telitacicept differentiated versus FcRn therapies? Is it more percentage of the patients that respond at all or proportion of patients that achieve deeper responses over time?

Jean-Paul KressCEO

Commercially, breadth is probably the most important thing here.

Jean-Paul KressCEO

Okay. Physicians and patients, they want to know if the product they are either prescribing or receiving will work.

Jean-Paul KressCEO

The current therapies, FcRns and complement inhibitors, they usually are 20%-40% of non-responders, which is not great. There is a high unmet medical need for therapies where you have a better certitude of getting a response, which means breadth. For that, our China data are unparalleled. We know that in our global trial, we'll probably get something about more than 50% of patients who will hit more than five MG-ADL improvement. Anything like that will be great and will improve the standard of care. So breadth. But depth and durability are also very important, and here as well, what our Chinese colleagues have generated with the asset are best in disease. Anything about two MG-ADL improvement versus placebo will be great.

Jean-Paul KressCEO

As long as it's durable and meaningful, this is what we're trying to have in our global trial, ongoing trial. I forgot to mention that our phase III trial is actually recruited. We announced that in September. We're getting closer to the event for this trial, and we've announced that we will have the readout in the first half of 2027. We're looking forward to obviously commenting on the data, which hopefully will cover breadth, durability, and depth.

Farzin HaqueBiotechnology Equity Research Analyst

Got it. For the key secondary endpoint, the QMG. The China QMG data was almost exactly in line with the global network analysis. What's the placebo-adjusted delta would you consider a clear win?

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day